TY - JOUR
T1 - Tumor burden score predicts tumor recurrence of non-functional pancreatic neuroendocrine tumors after curative resection
AU - Dong, Ding Hui
AU - Zhang, Xu Feng
AU - Lopez-Aguiar, Alexandra G.
AU - Poultsides, George
AU - Makris, Eleftherios
AU - Rocha, Flavio
AU - Kanji, Zaheer
AU - Weber, Sharon
AU - Fisher, Alexander
AU - Fields, Ryan
AU - Krasnick, Bradley A.
AU - Idrees, Kamran
AU - Smith, Paula M.
AU - Cho, Cliff
AU - Beems, Megan
AU - Schmidt, Carl R.
AU - Dillhoff, Mary
AU - Maithel, Shishir K.
AU - Pawlik, Timothy M.
N1 - Publisher Copyright:
© 2019 International Hepato-Pancreato-Biliary Association Inc.
PY - 2020/8
Y1 - 2020/8
N2 - Background: To investigate the feasibility of Tumor Burden Score (TBS) to predict tumor recurrence following curative-intent resection of non-functional pancreatic neuroendocrine tumors (NF-pNETs). Method: The TBS cut-off values were determined by a statistical tool, X-tile. The influence of TBS on recurrence-free survival (RFS) was examined. Results: Among 842 NF-pNETs patients, there was an incremental worsening of RFS as the TBS increased (5-year RFS, low, medium, and high TBS: 92.0%, 73.3%, and 59.3%, respectively; P < 0.001). TBS (AUC 0.74) out-performed both maximum tumor size (AUC 0.65) and number of tumors (AUC 0.5) to predict RFS (TBS vs. maximum tumor size, p = 0.05; TBS vs. number of tumors, p < 0.01). The impact of margin (low TBS: R0 80.4% vs. R1 71.9%, p = 0.01 vs. medium TBS: R0 55.8% vs. R1 37.5%, p = 0.67 vs. high TBS: R0 31.9% vs. R1 12.0%, p = 0.11) and nodal (5-year RFS, low TBS: N0 94.9% vs. N1 68.4%, p < 0.01 vs. medium TBS: N0 81.8% vs. N1 55.4%, p < 0.01 vs. high TBS: N0 58.0% vs. N1 54.2%, p = 0.15) status on 5-year RFS outcomes disappeared among patients who had higher TBS. Conclusions: TBS was strongly associated with risk of recurrence and outperformed both tumor size and number alone.
AB - Background: To investigate the feasibility of Tumor Burden Score (TBS) to predict tumor recurrence following curative-intent resection of non-functional pancreatic neuroendocrine tumors (NF-pNETs). Method: The TBS cut-off values were determined by a statistical tool, X-tile. The influence of TBS on recurrence-free survival (RFS) was examined. Results: Among 842 NF-pNETs patients, there was an incremental worsening of RFS as the TBS increased (5-year RFS, low, medium, and high TBS: 92.0%, 73.3%, and 59.3%, respectively; P < 0.001). TBS (AUC 0.74) out-performed both maximum tumor size (AUC 0.65) and number of tumors (AUC 0.5) to predict RFS (TBS vs. maximum tumor size, p = 0.05; TBS vs. number of tumors, p < 0.01). The impact of margin (low TBS: R0 80.4% vs. R1 71.9%, p = 0.01 vs. medium TBS: R0 55.8% vs. R1 37.5%, p = 0.67 vs. high TBS: R0 31.9% vs. R1 12.0%, p = 0.11) and nodal (5-year RFS, low TBS: N0 94.9% vs. N1 68.4%, p < 0.01 vs. medium TBS: N0 81.8% vs. N1 55.4%, p < 0.01 vs. high TBS: N0 58.0% vs. N1 54.2%, p = 0.15) status on 5-year RFS outcomes disappeared among patients who had higher TBS. Conclusions: TBS was strongly associated with risk of recurrence and outperformed both tumor size and number alone.
UR - https://www.scopus.com/pages/publications/85076249850
U2 - 10.1016/j.hpb.2019.11.009
DO - 10.1016/j.hpb.2019.11.009
M3 - 文章
C2 - 31822386
AN - SCOPUS:85076249850
SN - 1365-182X
VL - 22
SP - 1149
EP - 1157
JO - HPB
JF - HPB
IS - 8
ER -